Form 4: Tourmaline Bio Officer Sells Shares in Novartis Merger

Kevin Bruce Johnson, Chief Regulatory Officer of Tourmaline Bio, Inc., disposed of all his common stock and stock options as part of the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Kevin Bruce Johnson, Chief Regulatory Officer of Tourmaline Bio, Inc. (TRML), reported changes in beneficial ownership due to the company's merger with Novartis AG.
• The merger, pursuant to an Agreement and Plan of Merger dated September 8, 2025, involved Novartis AG acquiring Tourmaline Bio, Inc. through its subsidiary, Torino Merger Sub Inc.
• On October 28, 2025, Merger Sub completed a cash tender offer to acquire all outstanding common stock of Tourmaline Bio, Inc. for $48.00 in cash per share.
• Mr. Johnson disposed of 40,538 shares of common stock and an additional 11,046 restricted shares, which became fully vested and were treated as common stock in the merger, all for $48.00 per share.
• All outstanding and unexercised employee stock options held by Mr. Johnson were canceled and converted into a cash payment.
• The cash payment for options was calculated as the product of (i) the difference between the $48.00 Merger Consideration and the option's exercise price, and (ii) the number of shares issuable upon exercise.
• Options disposed included 96,146 shares at an exercise price of $7.9, 46,774 shares at $9.46, and 58,000 shares at $17.
• Following these transactions, Mr. Johnson beneficially owns 0 shares of common stock and 0 derivative securities.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the filing confirms the successful completion of a merger at a premium, resulting in a cash payout for shareholders and option holders. This represents a successful outcome for the company's equity holders.

Positives

• Shareholders, including the reporting person, received a cash payout of $48.00 per share, indicating a successful acquisition.
• Employee stock options were cashed out, providing liquidity to the reporting person based on the difference between the merger consideration and their exercise prices.
• The completion of the merger provides a clear exit strategy and value realization for Tourmaline Bio, Inc. shareholders.

Negatives

• Tourmaline Bio, Inc. ceases to be an independent publicly traded entity, removing its stock from the market.
• The reporting person no longer holds equity in the company, eliminating future upside potential from Tourmaline Bio's independent operations.

Future Outlook

The filing reports the completion of the acquisition of Tourmaline Bio, Inc. by Novartis AG, indicating that Tourmaline Bio, Inc. will no longer operate as an independent public entity. There are no forward-looking statements regarding Tourmaline Bio's future as a standalone company.

Industry Context

This transaction reflects ongoing consolidation within the biopharmaceutical industry, where larger pharmaceutical companies like Novartis AG acquire smaller biotech firms to expand their pipelines and therapeutic areas. Such mergers often provide significant premiums to shareholders of the acquired company.

Stakeholder Impact

• Shareholders received $48.00 per share in cash, realizing value from their investment.
• Employees holding stock options, such as the reporting person, received cash payouts for their vested options.
• The company's independent operations will cease, impacting its employees and potentially its strategic direction under new ownership.

Next Steps

• Tourmaline Bio, Inc. will be integrated into Novartis AG, ceasing to exist as an independent public company.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis AG, Merger, Acquisition, SEC Form 4, Insider Transaction, Stock Options, Common Stock, Cash Tender Offer, Chief Regulatory Officer